Form 4: Zymeworks CSO Reports RSU Vesting, Tax-Related Stock Sales

Zymeworks Inc.'s Chief Scientific Officer, Paul Andrew Moore, reported the vesting of restricted stock units and subsequent non-discretionary sales to cover tax obligations.

Summary

• Paul Andrew Moore, Chief Scientific Officer of Zymeworks Inc., reported transactions on January 5, 2026.
• Moore acquired 17,168 shares of common stock upon the vesting of one-third of Restricted Stock Units (RSUs) granted on January 5, 2023.
• Moore acquired an additional 20,000 shares of common stock upon the vesting of one-third of RSUs granted on January 5, 2024.
• Moore disposed of a total of 20,110 shares of common stock (9,289 shares and 10,821 shares) at a weighted average price of $25.0969 per share.
• These dispositions were mandatory 'sell to cover' transactions to satisfy tax withholding obligations and other applicable fees, not discretionary sales.
• Following these reported transactions, Moore beneficially owns 40,391 shares of common stock directly and 20,000 Restricted Stock Units directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting and tax-related sales) which are neutral in sentiment. It reflects standard executive compensation practices without indicating significant positive or negative operational news.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the executive's continued long-term incentive alignment with the company's performance.
• The executive received 37,168 shares of common stock from RSU vesting, reflecting earned compensation.

Negatives

• The executive sold 20,110 shares of common stock to cover tax withholding obligations, which reduces their direct share ownership in the company.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This is a routine insider transaction report and does not provide information relevant to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: The transactions represent a routine part of executive compensation, with a portion of vested shares sold to cover taxes, which is a common practice and generally has minimal impact on the company's overall share structure or valuation.

Key Dates

Keywords

Zymeworks, ZYME, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Paul Andrew Moore, Chief Scientific Officer, Sell to Cover, Beneficial Ownership